Vertex Leads Race to Tap Growing Demand for Safer Pain Drugs as Opioid Alternative
-
The pain management market is huge and growing, expected to reach over $108 billion by 2032. There is demand for safer, non-opioid options.
-
Vertex aims to submit its non-opioid pain drug, VX-548, for approval mid this year. Pivotal trial data was positive. It could be the first such drug approved.
-
Latigo emerged with $135M to develop a similar NaV1.8 inhibitor for pain. But it is years behind Vertex in development.
-
Vertex is an established, profitable company well positioned to launch a new pain drug. Latigo lacks infrastructure currently.
-
The multi-billion dollar pain market has room for multiple successful drugs. Latigo doesn't threaten Vertex's prospects if approved later.